Melanoma Management in 2024

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 75 Minutes

Overview

This program offers a focused exploration of the standard guidelines and best practices for managing primary melanoma, including the timing and interpretation of sentinel node biopsy results, as well as the role of adjuvant therapy in optimizing patient outcomes.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Describe the standard guideline treatment for managing primary melanoma

2. Recognize the appropriate timing for a sentinel node biopsy and what to do with the results 

3. Identify the place of adjuvant therapy in the management of melanoma and their expected outcomes 

                                                                                                 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Course opens: 
04/19/2024
Course expires: 
04/19/2025
Cost:
$0.00
Rating: 
0

Faculty

Jonathan Zager, MD, FACS, FSSO 

Dr. Jonathan Zager is the Chief Academic Officer and a surgical oncologist and Senior Member in the Departments of Cutaneous Oncology and Sarcoma at Moffitt Cancer Center. Dr. Zager is the Director of Regional Therapies at Moffitt’s Donald A. Adam Comprehensive Melanoma Research Center. Dr. Zager is the Chair of the Department of Oncologic Sciences and a Professor of Surgery at the University of South Florida, Morsani School of Medicine. Dr. Zager’s research and clinical interests include the regional therapy treatment of cutaneous melanoma and non-melanoma skin cancers, soft tissue sarcomas.

Dr. Zager is internationally known for the management and study of locoregionally recurrent melanoma, non-melanoma skin cancer and soft tissue sarcoma. In particular conducting clinical trials for these clinical scenarios using regional therapies such as, intralesional injections using oncolytic viruses and isolated limb infusions for in transit or recurrent extremity melanoma and unresectable extremity sarcomas as well as performing percutaneous hepatic perfusions for unresectable melanoma to the liver. Dr Zager handy published over 300 peer reviewed papers, numerous chapters and edited textbooks and presented over 500 podium talks, invited grand rounds and lectures worldwide.  Dr. Zager is the Director of Student Research in the Department of Cutaneous Oncology including the 8 week Summer Student Research Internship and the Program Director of the Surgical Oncology Research Fellowship Program.  Dr. Zager serves as Moffitt Cancer Center's Designated Institutional Official for their ACGME.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Jonathan Zager, MD, FACS, FSSO discloses speaker’s bureau with Castle Biosciences and Merit Medical, advisory boards with Merck, and contracted research with Delcath, Philogen, Provectus, SWOG during the past 24 months.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above